Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm, Appendix 4C - Quarterly (ASX:NOX)

Noxopharm (ASX: NOX) today releases its Appendix 4C for the quarter ending 30 September 2019, as well as providing guidance for the next 12 months. For more information, download the attached PDF...read more

Noxopharm, Dr Graham Kelly to Assume CEO Role (ASX:NOX)

Noxopharm (ASX: NOX) announces that Dr Graham Kelly will assume the duties of interim CEO following the departure of former CEO, Dr Greg van Wyk. While the Board understands that a dual CEO/Chair...read more

Noxopharm, NOX and Nyrada TechKnow Invest Roadshow Presentations (ASX:NOX)

Noxopharm (ASX: NOX) provides to the market the Noxopharm and Nyrada Inc corporate presentations ahead of the TechKnow Invest Roadshow 2019 in Sydney (October 22, 2019) and Melbourne (October 24, 20...read more

Durable Anti-Cancer Effect Confirmed in Noxopharm’s DARRT-1 Study (ASX:NOX)

Data on half of study patients after 6-month review to be presented to Australian cancer conference Nov 2019 Data suggests major anti-cancer effect of Veyonda/DARRT treatment regimen in l...read more

Noxopharm, Notice of 2019 Annual General Meeting & Proxy Form (ASX:NOX)

Notice is hereby given that an Annual General Meeting of Shareholders of Noxopharm Limited ACN 608 966 123 will be held at 2:00PM AEDT on 20 November 2019 at Museum of Sydney, corner of Phillip and ...read more

Noxopharm to Pursue Major Opportunity in Brain Cancer (ASX:NOX)

Potential for Fundamental Change in the Treatment of Brain Cancer Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most...read more

Noxopharm, New Executive Appointments and Board Change (ASX:NOX)

Noxopharm (ASX: NOX) announces details of changes to its senior executive and Board structures. For more information, download the attached PDF.

Noxopharm, Noxopharm 2019 Annual General Meeting Details (ASX:NOX)

Noxopharm (ASX: NOX) is pleased to announce details of its 2019 Annual General Meeting to the market. In addition to voting formalities, the Chair of the Board will present an overview of the yea...read more

Noxopharm Announce further Data Review Shows Major Clinical Benefits From Veyonda® (ASX:NOX)

Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer 177LuPSMA therapy is the su...read more

Noxopharm Annual Report Captures Positive Progress (ASX:NOX)

Noxopharm Annual Report released today Positive indications for clinical benefits of proprietary drug candidate Veyonda® continue Key commercialisation milestones met Sydne...read more

Noxopharm, Annual Report to Shareholders (ASX:NOX)

Noxopharm (ASX: NOX) is pleased to release its 2019 Annual Report. This has been an important year for Noxopharm with new trial data continuing to indicate positive clinical benefits of its front...read more

Noxopharm, Departure of Dr Wan Wyk (ASX:NOX)

Noxopharm (ASX:NOX) announces today that Dr Greg Van Wyk is departing the business. Dr Van Wyk, who has been with Noxopharm for 10 months and was initially employed as its Chief Medical Officer, has...read more

Noxopharm Announce Veyonda and Radiotherapy Profiled at Key Oncology Meeting (ASX:NOX)

Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meeting Both Noxopharm and independent investigators have abs...read more

Noxopharm, Results of Meeting (ASX:NOX)

A summary of valid and eligible proxies received for the above meeting was as follows... For more information, download the attached PDF.

Noxopharm, NOX EGM Chairman's Address and Presentation (ASX:NOX)

Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases the Chairman’s Address and Presentation for today’s Extraordinary General Meeting. F...read more

Viewing: 46 - 60 of 169 Previous | Next